INMD Add to watchlist $14.25 +0.11 (+0.78%) Last updated: Apr 16, 2026 02:38
52-Week Range
$14.25
$12.72 $14.25 $16.74

Fundamentals Overview

InMode Ltd. is in the middle of its 52-week range with low valuation, trading relatively flat today.

Valuation low

P/E 9.7 P/B 1.32 P/S 2.44

Intrinsic value (DCF)

+126.5% upside vs price

Profitability

Net margin 25.3%

Risk (Beta)

2.12 — higher vol

Earnings & growth

EPS $1.46 Rev +11.5% Profit +23.6% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 53% confidence Risk: High Volatility — Beta 2.12. Consider smaller position size due to higher beta.

Supporting (Buy):

DCF +126.5% upside vs price · Analyst grade: A

Pressures (Sell):

Sentiment weakening (4 downgrades) · Beta 2.12 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$902.86M
P/E (TTM)
9.73
EPS (TTM)
$1.46
Dividend Yield
N/A
52-Week Range
$12.72 - $16.74
Volume vs Avg
N/A
Beta
2.12

About

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in wom...
Sector: Healthcare
Headquarters: IL
Employees: 599
IPO Date: Aug 2019
Beta: 2.12 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: majority downgrades. Current institutional positions: Hold: 15, Neutral: 5, Overweight: 10.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $32.28; current price is $14.25. That’s a +126.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 9.73
DCF value (model) $32.28 (126.5% upside)
PEG (TTM) N/A
P/B (TTM) 1.32
P/S (TTM) 2.44
P/FCF (TTM) 10.1
Liquidity & enterprise
Current Ratio (TTM) 9.88
Quick Ratio (TTM) 8.61
Cash Ratio (TTM) 4.28
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 25.33%
Gross margin (TTM) 78.54%
Operating margin (TTM) 23.05%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for INMD.

Analyst Sentiment at a Glance

A Sentiment Weakening
Hold 15Neutral 5Overweight 10
0 upgrades, 4 downgrades
Price Target Consensus
Current $14.25
Median $16.00
Consensus $16.00
Low consensus $15.00
High consensus $17.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Canaccord Genuity maintain Hold Hold 2025-12-17
UBS maintain Neutral Neutral 2025-11-06
Needham maintain Hold Hold 2025-10-10
Canaccord Genuity maintain Hold Hold 2025-10-10
Needham maintain Hold Hold 2025-07-30
Barclays maintain Overweight Overweight 2025-07-30
Canaccord Genuity maintain Hold Hold 2025-07-11
Barclays maintain Overweight Overweight 2025-04-30
Canaccord Genuity maintain Hold Hold 2025-04-29
UBS maintain Neutral Neutral 2025-04-29
BTIG downgrade Buy Neutral 2025-04-29
Needham maintain Hold Hold 2025-04-28
Jefferies maintain Hold Hold 2025-04-14
Needham maintain Hold Hold 2025-04-14
Needham maintain Hold Hold 2025-04-09
Barclays maintain Overweight Overweight 2025-02-05
Needham maintain Hold Hold 2025-02-04
Barclays maintain Overweight Overweight 2025-01-09
Barclays maintain Overweight Overweight 2024-10-14
Jefferies downgrade Buy Hold 2024-07-23
Barclays maintain Overweight Overweight 2024-07-15
Canaccord Genuity maintain Hold Hold 2024-07-12
Barclays maintain Overweight Overweight 2024-04-12
Barclays maintain Overweight Overweight 2024-02-15
UBS maintain Neutral Neutral 2024-02-14
Barclays maintain Overweight Overweight 2024-01-18
Barclays maintain Overweight Overweight 2024-01-04
Canaccord Genuity maintain Hold Hold 2023-12-07
UBS downgrade Buy Neutral 2023-11-03
Canaccord Genuity downgrade Buy Hold 2023-10-13